Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,601–3,700 of 4,628
Gezer, N. S. (2024) · Türk Radyoloji Seminerleri · doi:10.4274/trs.2024.23114 · Cited by 2
Matson, S. M., & Lee, J. S. (2024) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2023.07.005 · Cited by 1
New Therapies in Outpatient Pulmonary Medicine
Granados, L., John, M. M., & Edelman, J. D. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.011 · Cited by 1
Tyker, A., Morisset, J., & Ryerson, C. J. (2024) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2024.2368854 · Cited by 1
Approach to the patient with Childhood Interstitial and Diffuse Lung Disease
Fiorino, E. K., & Fishman, M. P. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27162 · Cited by 2
A Jaw-Dropping Consequence: Nintedanib’s Role in Osteonecrosis of the Jaw
Rai, O., Romero, K. N., Shaykh, N., et al. (2024) · Cureus · doi:10.7759/cureus.65689 · Cited by 1
“Nintedanib is a small molecule tyrosine kinase inhibitor that competitively binds to multiple factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) [1,2].”
BackgroundVašáková, M., Gregor, J., Moğulkoç, N., Kramer, M. R., Lewandowska, K. B., Šterclová, M., Müller, V., Slivka, R., Studnicka, M., Plackova, M., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107791 · Cited by 1
Factors associated with non-intervention of antifibrotic agents in IPF patients
Asami‐Noyama, M., Hamada, K., Asai, Y., Abé, T., Yonezawa, K., Watanabe, M., Hisamoto, Y., Murakawa, K., Fukatsu, A., Matsuda, K. M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.09.008 · Cited by 2
Tetikkurt, C. (2024) · doi:10.69860/nobel.9786053359517 · Cited by 1
Lung Fibrosis on CT Imaging: Essentials and Updates
Canivet, P., & Coche, E. (2024) · Journal of the Belgian Society of Radiology · doi:10.5334/jbsr.3775 · Cited by 1
Genetic and molecular drivers of scleroderma pathogenesis
Odell, I. D. (2024) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2024.12.007 · Cited by 1
Okamoto, M., Fujimoto, K., Chikasue, T., Yanagihara, T., Tabata, K., Zaizen, Y., Tominaga, M., Sumi, A., Takeoka, H., Matsuo, N., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.005 · Cited by 2
Bellani, S., & Spagnolo, P. (2024) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001055 · Cited by 1
Nakayasu, H., Karayama, M., Enomoto, N., Inoue, Y., Yasui, H., Suzuki, Y., Hozumi, H., Furuhashi, K., Kono, M., Toyoshima, M., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.011 · Cited by 3
Self-citationOkamoto, M., Yanagihara, T., Fujimoto, K., Chikasue, T., Tabata, K., Zaizen, Y., Tominaga, M., Sumi, A., Nishii, Y., Matsuo, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247865 · Cited by 1
Innovation through imitation: IL-33 decoys show promise in pulmonary fibrosis
Kotas, M. E., & Gordon, E. D. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2024.100035 · Cited by 1
Matsumoto, M., Minegishi, Y., Higa, K., Fukuizumi, A., Onda, N., Takeuchi, S., Miyanaga, A., Gemma, A., & Seike, M. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03459-y · Cited by 1
Zhao, R., Tao, X., Zhang, W., Li, S., Zhou, S., Ning, A., Li, Z., Chu, M., Wang, W., & Jiang, J. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117679 · Cited by 1
Pal, R., Barney, A. M., Sgalla, G., Walsh, S. L. F., Sverzellati, N., Fletcher, S., Cerri, S., Cannesson, M. P., & Richeldi, L. (2025) · Physiological Measurement · doi:10.1088/1361-6579/ada9c0 · Cited by 1
Self-citationAyçiçek, O., Keskin, S., Haciosmanoglu, M., Öztuna, F., Bülbül, Y., & Özlü, T. (2025) · Medicina · doi:10.3390/medicina61020283 · Cited by 1
“Many clinical studies have shown that these two drugs slow down the rate of decline in functional residual capacity, decrease the number of exacerbations and improve survival rates in IPF [5,11,12].”
Rezapour, A., Sheikhrobat, M. V., Souresrafil, A., Moeini, S., Roghani, T., Sayyad, A., & Ghorrabi, A. T. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2480718 · Cited by 1
Rheumatoide Arthritis: Screening für Lungenmanifestationen und Management
Schneider, U., & Krause, A. (2025) · Zeitschrift für Pneumologie · doi:10.1007/s10405-025-00611-1 · Cited by 1
Nishikiori, H., Nakamura, K., Takei, R., Kondoh, Y., Suda, T., & Chiba, H. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.04.008 · Cited by 2
Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis
Sumiya, R., Banno, T., Ueno, H., Hirayama, S., & Suzuki, K. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2854 · Cited by 3
Marinescu, D.-C., & Ryerson, C. J. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.12.005 · Cited by 1
Influence of Race and Ethnicity on the Precision Diagnosis and Treatment of ILD
Ferraro, V., & Morisset, J. (2025) · Respiratory medicine · doi:10.1007/978-3-031-87183-2_7 · Cited by 1
Itano, J., Ishiga, M., Fujii, M., Takemoto, M., Hayashibara, N., Kimura, G., & Tanimoto, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4493-24 · Cited by 2
Yi-Fei-Tong-Bi Decoction Alleviates Bleomycin Induced Pulmonary Fibrosis in Mice
Du, K., Wen, X., Zhu, J., Liang, R., Wang, L., Li, N., & Zou, Q. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s515368 · Cited by 1
Chen, C., Han, Z., Luo, J., Wang, J., Liu, T., Zhang, J., & Zhang, C. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156922 · Cited by 2
Cheng, H., Gao, T., Sun, Y., Huang, F., Gu, X., Shan, C., Luo, S., & Wang, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00604.2024 · Cited by 3
Progressive pulmonary fibrosis: current perspectives in diagnostic imaging
Agarwal, P., Schlett, C. L., Bamberg, F., & Frye, B. C. (2024) · BJR|Open · doi:10.1093/bjro/tzaf018 · Cited by 2
Okamoto, M., Yanagihara, T., Zaizen, Y., Fujimoto, K., Chikasue, T., Sumi, A., Tabata, K., Tominaga, M., Matsuo, N., Nouno, T., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.014 · Cited by 1
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Kim, S., Kim, Y., Kim, T. S., Kang, J.-H., Yun, I.-Y., Lee, E.-S., Lee, E. J., Kim, R.-K., Yi, J. M., Choi, H. S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02421-6 · Cited by 4
Hartmann, S., Janssen, J. M., Ribbing, J., Stowasser, S., & Korell, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70132 · Cited by 1
Self-citationBiomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?
Ask, K., Hambly, N., & Kolb, M. R. J. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0123-7 · Cited by 2
Self-citationAtención al final de la vida en los pacientes con fibrosis pulmonar idiopática
Miranda, D. G., Peces, E. M. S., Babarro, A. A., et al. (2014) · Medicina Paliativa · doi:10.1016/j.medipa.2014.07.001 · Cited by 1
Review of the British Thoracic Society Winter Meeting 2013, 4–6 December, London, UK
Chalmers, J. D., Greening, N. J., José, R. J. P., & Janes, S. M. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205177 · Cited by 2
Primer Consenso Mexicano sobre Fibrosis Pulmonar Idiopática
Mejía, M. E., Buendía-Roldán, I., Mateos‐Toledo, H., Estrada, A., Espinoza-Hernández, M., Juárez-Hernández, F., Vargas-Domínguez, C., & Selman, M. (2016) · NCT Neumología y Cirugía de Tórax · doi:10.35366/65161 · Cited by 8
Self-citationATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum
Michaud, G. C., Channick, C. L., Law, A. C., McCannon, J. B., Antkowiak, M., Garrison, G. W., Sayah, D. M., Huynh, R. H., Brady, A. K., Adamson, R., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201601-060cme · Cited by 1
Imaging of Diffuse Lung Disease
Chung, J. H., & Kanne, J. P. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000203 · Cited by 1
The evaluation of disease severity/staging for prognosis
O’Connell, O. J., & Egan, J. J. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005315 · Cited by 1
Drug Development and Regulatory Considerations for SSc Therapies
Wright, T. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_43 · Cited by 1
Traitement de la fibrose pulmonaire idiopathique : approche médicamenteuse
Blin, E., & Cottin, V. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30059-3 · Cited by 1
Self-citationNintedanib—Nowa opcja terapeutyczna dla chorych na samoistne włóknienie płuc
Majewski, S., & Piotrowski, W. J. (2016) · Advances in respiratory medicine · doi:10.5603/arm.46993 · Cited by 1
Drug Discovery in Tissue Fibrosis
Pinto, S., Hoek, M., Huang, Y., Costet, P., Ma, L., & Imbriglio, J. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12432-1 · Cited by 2
Akute Exazerbation der IPF – revidierte Definition und Diagnosekriterien
Markart, P., & Günther, A. (2017) · Pneumo News · doi:10.1007/s15033-017-0601-4 · Cited by 1
Downey, G. P., & Aschner, Y. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1921ed · Cited by 1
Condoluci, C., Inchingolo, R., Mastrobattista, A., Comes, A., Golfi, N., Boccabella, C., & Richeldi, L. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002017 · Cited by 2
Self-citationMeng, L., Wang, C., Wang, Z., et al. (2018) · Traditional Medicine and Modern Medicine · doi:10.1142/s2575900018500052 · Cited by 1
Acute exacerbation of idiopathic pulmonary fibrosis
Avdeev, S. N. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-4-469-482 · Cited by 3
Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Kishaba, T. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.84 · Cited by 1
The Hypoxic Adenosine Response and Inflammation in Lung Disease
Philip, K., & Blackburn, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00002-9 · Cited by 1
Treatment of severe idiopathic pulmonary fibrosis—is sildenafil the next (in)stage?
Hayton, C., Craig, C., & Chaudhuri, N. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.33 · Cited by 1
Wang, J., Parys, M. V., Pan, L., Chen, Y., Cheung, D. S., McKnight, J., Milanowski, D. J., Ding, X., & Dean, B. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4482 · Cited by 1
Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis
Mason, W. R., McLaughlin, S., Dedopoulos, S., Mahoney, E., Meadows, T., Stauffer, J. L., & LANCASTER, L. H. (2019) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x15666190212155051 · Cited by 1
4. Recent Progress in Diagnosis and Treatment of Interstitial Pneumonias
Nishioka, Y. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.505 · Cited by 1
Galindo, J. L., Celis-Preciado, C. A., Pontificia Universidad Javeriana. Bogotá, C., Mejía, M. E., & Unidad de Enfermedades Pulmonares Intersticiales. Instituto Nacional de Enfermedades Respiratorias, I. C. V. C. D. M. (2018) · Investigación Clínica · doi:10.22209/ic.v59n4a07 · Cited by 1
The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
LIMPER, A. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1298ed · Cited by 2
In search for a predictive marker of acute exacerbations of idiopathic pulmonary fibrosis
Moodley, Y. P. (2019) · Respirology · doi:10.1111/resp.13666 · Cited by 1
Scott, D. A., Loveman, E., Colquitt, J. L., & O’Reilly, K. M. (2019) · Medicina · doi:10.3390/medicina55080443 · Cited by 1
“INPULSIS 2 [21], Phase II % predicted at 52 weeks; Litres at 52 weeks X X c X c X Not included X”
BackgroundInfluentialIdiopathic interstitial pneumonias
Averyanov, A., Коган, Е. А., Lesnyak, V., Stepanyan, I. E., & Васильевна, Д. О. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815375-8.00002-9 · Cited by 1
Genetic Determinants of Interstitial Lung Diseases
Mathai, S. K., Schwartz, D. A., & Borie, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00015-x · Cited by 1
Neue Wege in der Therapie der SSc-ILD: Was macht Sinn?
Kreuter, M., & Hoffmann‐Vold, A. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00704-2 · Cited by 1
End-of-Life Care of Patients with Idiopathic Pulmonary Fibrosis
Micco, A., Sorbo, A. D., & Donno, M. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-26664-6_33 · Cited by 1
Recent developments in interstitial lung diseases
Demirağ, F. (2019) · Journal of Current Pathology · doi:10.5146/jcpath.2019.56 · Cited by 1
Genetics of Idiopathic Pulmonary Fibrosis
Mathai, S. K., & Schwartz, D. A. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_6 · Cited by 1
LANCASTER, L. H., Valenzuela, C., Mason, W. R., Neurohr, C., Ripamonti, E., Kirchgaessler, K.-U., & Cottin, V. (2020) · Pulmonary Therapy · doi:10.1007/s41030-020-00111-y · Cited by 1
Self-citationAcute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
Kim, D. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00011-2 · Cited by 1
Self-citationCarrera, L. G., & Álvarez-Sala, J. L. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.06.004 · Cited by 2
Idiopathic Interstitial Pneumonias
Ryu, J. H., Selman, M., Colby, T. V., & King, T. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00063-4 · Cited by 2
Self-citationAboudara, M. C., & Maldonado, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2995
Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics
Bendstrup, E. M., & Kalluri, M. (2020) · Drug Safety · doi:10.1007/s40264-020-00991-8 · Cited by 1
Nintedanib for the treatment of idiopathic pulmonary fibrosis: An Indian perspective
Kishore, K., Singh, A., Verma, A., & Singh, A. (2020) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_35_19 · Cited by 1
Idiopatic pulmonary fibrosis: A simple approach to a complex problem
Alvarado, A. (2020) · Clinical Research and Trials · doi:10.15761/crt.1000309 · Cited by 1
Antifibrotische Therapie – neue Indikationen bei Non-IPF-interstitiellen Lungenerkrankungen
Markart, P., Drakopanagiotakis, F., & Wygrecka, M. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1239-3728 · Cited by 1
“Beide Substanzen führen bei IPF-Patienten zu einer signifikanten Verringerung des jährlichen lungenfunktionellen Abfalls im Vergleich zu Placebo [2, 3].”
BackgroundCurrent and future treatment for idiopathic pulmonary fibrosis
Choi, W.-I. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.256 · Cited by 1
Treatment of chronic fibrosing interstitial lung diseases
Lee, J. M. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.277 · Cited by 1
“IPF 환자를 대상으로 한 INPULSIS (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis) 연구에서는 닌테다닙을 복용한 IPF 환자는 위약 투여 환자군 대비 연간 FVC의 감 소가 약 50%까지 유의하게 줄었다[40].”
Strykowski, R. K., & Adegunsoye, A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103373 · Cited by 1
“Widely used anti-fibrotic medications slow the rate of functional decline [2,3] but are often associated with adverse effects and persistently high symptom burden.”
BackgroundIdiopathic pulmonary fibrosis complications: what a radiologist should know
Mereu, M., Scutti, M., Veri, D., Conte, S., Patea, R. L., Calandriello, L., Palmucci, S., Valentini, A., Farchione, A., & Larici, A. R. (2021) · Journal of Radiological Review · doi:10.23736/s2723-9284.21.00136-0 · Cited by 1
Kouroki, M., Inagaki, J., Fujisaki, T., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29211 · Cited by 1
Fibrosis pulmonar idiopática. Características clínicas de un registro en Panamá. 2017-2020
Noriega, L., Guevara, E., Jiménez, R., Jaramillo, F., Márquez, F., Perea, T., & Evia, E. (2021) · Revista médica de Panamá · doi:10.37980/im.journal.rmdp.20211809 · Cited by 1
Sjögren’s Syndrome and The Respiratory System: A Comprehensive Approach
Mahmood, F., Ehtesham, M., Bokhari, S. M. M. A., & Peredo-Wende, R. (2021) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2021/2.1176 · Cited by 1
González-García, M., Rincón-Álvarez, E., Rodríguez-Cortés, C., et al. (2021) · Acta Médica Colombiana · doi:10.36104/amc.2022.2017 · Cited by 1
Vancheri, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005715 · Cited by 1
(2016) · Australian Prescriber · doi:10.18773/austprescr.2016.030 · Cited by 1
Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Wu, X., Kaner, R. J., & Martínez, F. J. (2017) · Barcelona Respiratory Network · doi:10.24875/brn.m17000009 · Cited by 1
Rowlands, B., Mehta, P., & Gunawardena, H. (2021) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.332986 · Cited by 1
Modern principles and prospects for drug therapy of interstitial lung diseases in children
Лев, Н. С., & Mizernitsky, Y. L. (2022) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2022-67-3-18-22 · Cited by 1
Neumonías intersticiales idiopáticas
Velasco, D., Alonso, I. J., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.011 · Cited by 2
Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?
Wong, M. (2022) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2022.v28i4.283 · Cited by 1
Successful nintedanib desensitization: Due to two cases
Tepetam, F. M., Özden, Ş., & Duman, D. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239912 · Cited by 1
Ntiamoah, P., Purpura, R., Vehar, S. J., Coley, C., Hasvold, J., Schmidt, L. A., Flaherty, K. R., & Tolle, L. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_34 · Cited by 2
Self-citationNagano, N., Tokunaga, N., Ikeda, M., Inoura, H., Duong, K., Miwa, M., Sohrab, M. G., Topić, G., Itoh, M. N., & Takamura, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-32915-8 · Cited by 1
Zarogoulidis, P., Matthaios, D., Huang, H., et al. (2023) · Medicina · doi:10.3390/medicina59040787 · Cited by 1
“Surgical lung biopsy is currently considered the gold standard for a definitive histological diagnosis in over 90% of cases [2,5,6].”
BackgroundNintedanib-Induced Gastric Antral Vascular Ectasia in Patients With Idiopathic Pulmonary Fibrosis
Takahashi, T., Sato, Y., Kashihara, T., Miyata, Y., Fujino, Y., Mitsui, Y., Okamoto, K., Miyamoto, H., Nishioka, Y., & Takayama, T. (2023) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001107 · Cited by 1
Cottin, V., & Cordier, J.-F. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.10.725
Self-citationJankowich, M. D., & Rounds, S. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018614 · Cited by 1
Pulmonary and Critical Care Medicine
Kruse, D. A., & Bailey, K. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-31831-8_27 · Cited by 1
Clinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Jones, R. (2016) · Cited by 1
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.